# Arima Genomics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/arima-genomics

- Industry: Medical Devices & Equipment
- Headquarters: San Diego, US
- Website: www.arimagenomics.com
- Total disclosed funding: $29M
- Latest round: Series C (Jun 16, 2025)
- Investors on record: 10

## About

Founded in 2015 and based in San Diego, US, Arima Genomics, Inc. operates as a biotechnology company thats develops genomic solutions focused on advancing genomic research through innovative 3D technology solutions that enhance the understanding of genetic information. It supports researchers in uncovering critical insights into genome structure and function. In June 2025, Arima Genomics raised USD 22 million in series C funding led by new investor Illumina Ventures, with participation from returning investors Co-Win Ventures and Berkeley Catalyst Fund. Individual investors also participated in the round. Sid Selvaraj, a co-founder and currently the CEO, has been pivotal in the company's direction and strategic initiatives.Arima Genomics specializes in genomic solutions, offering products like Genome-Wide HiC, Arima SV Detection Assay, HiC FFPE, and various capture HiC products. These offerings are designed to provide insights into genome structure and regulatory landscapes, particularly in cancer genomics, enabling researchers to identify biomarkers and therapeutic targets. Their services cater to academic institutions, biotech firms, and research labs across North America and Europe, with a focus on user-friendly workflows and integrated protocols to accelerate genomic discoveries.Revenue is primarily generated through the sale of genomic products and services, structured around project-based collaborations with research institutions and commercial partners. This includes direct sales of products like the Genome-Wide HiC and subscription access to the Arima Bioinformatics Platform. Contracts typically outline specific project goals, allowing for tailored solutions that address unique research needs, from sample processing to data interpretation. In June 2025, Arima Genomics raised USD 22 million in series C funding led by new investor Illumina Ventures, with participation from returning investors Co-Win Ventures and Berkeley Catalyst Fund. Individual investors also participated in the round. The company plans to use the June 2025 funding to support its initiative to launch its clinical pipeline for cancer diagnostics.

## Funding rounds

- Series C, Jun 16, 2025, $22M — Illumina Ventures, Co-Win Ventures, Berkeley Catalyst Fund
- Series B, Dec 22, 2021, $7M — Agilent Technologies, Ladder Capital Corp, Tech Coast Angels, Vectr Ventures, Co-Win Ventures, Genetron Holdings Limited, Berkeley Catalyst Fund, Hiaqua Investment, Inc.
- Series A, Feb 24, 2020 — Agilent Technologies Inc., Vectr Ventures, Co-Win Ventures, Berkeley Catalyst Fund

## Investors

- Agilent Technologies Inc. — Series A
- Vectr Ventures (https://capitalatlas.ai/funds/vectr-ventures) — Series A, Series B
- Co-Win Ventures (https://capitalatlas.ai/funds/co-win-ventures) — Series A, Series B, Series C
- Berkeley Catalyst Fund (https://capitalatlas.ai/funds/berkeley-catalyst-fund) — Series A, Series B, Series C
- Agilent Technologies — Series B
- Ladder Capital Corp — Series B
- Tech Coast Angels — Series B
- Genetron Holdings Limited — Series B
- Hiaqua Investment, Inc. — Series B
- Illumina Ventures (https://capitalatlas.ai/funds/illumina-ventures) — Series C